Pupillographic, tonographic and refractive parameter changes after topical instillation of Brimonidine tartrate 0.2% in healthy subjects

Acta Ophthalmologica Scandinavica, Supplement

Volumn 76, Issue 227, 1998, Pages 34-35

  Brogliatti, B ^a   Bogetto, C ^a   Prandi, B ^a   Boles Carenini, B ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; MIOTIC AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; QUINOXALINE DERIVATIVE;

ACCOMMODATION; ADULT; AQUEOUS HUMOR FLOW; CONFERENCE PAPER; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGING SYSTEM; MALE; MOTOR ACTIVITY; MYDRIASIS; NORMAL HUMAN; PARAMETERS OF MEASUREMENT AND ANALYSIS; PRIORITY JOURNAL; PUPIL; PUPIL REFLEX; REFRACTION INDEX; TOPICAL DRUG ADMINISTRATION; VIDEORECORDING; AQUEOUS HUMOR; ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; EYE REFRACTION; FOLLOW UP; INTRAOCULAR PRESSURE; OCULOPLETHYSMOGRAPHY; REFERENCE VALUE;

ACCOMMODATION, OCULAR; ADMINISTRATION, TOPICAL; ADRENERGIC ALPHA-AGONISTS; ADULT; AQUEOUS HUMOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAOCULAR PRESSURE; MALE; PUPIL; QUINOXALINES; REFERENCE VALUES; REFRACTION, OCULAR; TONOMETRY, OCULAR;

EID: 0032216718     PISSN: 13953931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Barnebey HS, Zimmerman TJ, Stanley B, et al. (1993): The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty. Ophthalmology 100: 7: 1083-1088.
2. Burke JA, Kharlamb A, Shan T, et al. (1995): Adrenergic and Imidazoline receptor-mediated responses to UK-14, 304-18 (Brimonidine) in rabbits and monkeys: a species difference. In: Reis D, Bousquet P, Parini A. The Imidazoline Receptor: Pharmacology, Functions, Ligands, and Relevance to Biology and Medicine. New York: The New York Academy of Sciences 763: 78-95.
3. Burke JA & Potter DE (1986). Ocular effects of a relatively selective alpha-2 agonist (UK-14, 304-18) in cats, rabbits and monkeys. Curr Eye Res 5: 665-676.
4. Burke J & Schwartz M (1996): Preclinical evaluation of brimonidine. Surv Ophthalmol 41 suppl 1: S9-S18.
5. Burke JA, Wheeler L, Manlapaz C, et al. (1996): Therapeutic use of α-2 adrenoceptor agonists in glaucoma. In Lanier S, Limbird L. Alpha-2 Adrenergic Receptors: Structure, Function and Therapeutic Implications. Reading, UK: Harwood Academic Publishers 179-187.
6. David R, Walters TR, Sargent JB, et al. (1995): The safety and hypotensive efficacy of Brimonidine Tartrate 0.08%, 0.02%, 0.35% and 0.5% in normotensive subjects. Eur J Ophthalmol 5 Abstract: 156.
7. Gabelt BT, Robinson JC, Hubbard WC, et al. (1994): Apraclonidine and Brimonidine effects on anterior ocular and cardiovascular physiology on normal and sympathectomized monkeys. Exp Eye Res 59: 633-644.
8. Harper D, Kelley E, Iacono T, et al. (1990): The safety, comfort, onset and duration of action of AGN 190342-LF in normal subjects. Clinical research report no. S342-107 7831 dated February, 1990.
9. Harper D, Kelley E, Walt J, et al. (1990): The safety, comfort, onset and duration of action of AGN 190342-LF in normal subjects. Report no. A 342-111-8177 dated February, 1990.
10. Harper D, Kelley E, Walt J, et al. (1990): The safety, comfort, onset and duration of action of AGN 190342-LF in normal subjects. Clinical research report no. S342-108-8042 dated August, 1990.
11. Morrison JC (1995): Side effects of α-2 adrenergic agonists. J Glaucoma 4 suppl.1: S36-S38.
12. Robin AL & Novack JD (1992): α-2 agonists in the therapy of glaucoma. In: Drance SM. ed. Pharmacology of Glaucoma. Baltimore: Williams and Wilkins, 103-124.
13. Schuman JS, Horwitz B, et al. (1997): A 1-year study of Brimonidine twice daily in glaucoma and ocular hypertension. Arch Ophthalmol 115: 847-852.
14. Walters TR (1996): Development and use of Brimonidine in treating acute and chronic elevation of intraocular pressure: a review of safety, efficacy, dose-response and dosing studies. Surv Ophthalmol 41: S19-S26.